Voichita Mihali watched through a microscope as tiny machines—150 times thinner than a human hair—clustered on the surface of cancer cells, like satellites locking onto a target. These aren’t science fiction props, but real modular nanorobots developed at the University of Basel, engineered to seek out and attack cancer cells with precision. Led by Professor Cornelia Palivan, the team has created a breakthrough system that could redefine how we treat disease, clean industrial waste, or catalyze chemical reactions—all from the scale of a billionth of a meter.
Unlike traditional nanorobots built for one narrow task, this new design is modular and reusable, combining a magnetic propulsion unit with a payload capsule that can carry enzymes or therapeutic agents. The two components snap together using a DNA-based “molecular Velcro,” where complementary strands guide self-assembly with remarkable precision. Once assembled, the nanorobot can be directed magnetically and programmed to dock at specific sites—like HeLa cancer cells—thanks to biomolecules on its surface that act as targeting signals.
Inside the payload capsule are four polymer vesicles, each shielding enzymes that can convert molecules from the environment into active compounds. In lab tests, when loaded with enzymes that produce an anticancer agent, the nanorobots reduced HeLa cell viability to just 16% within 72 hours—equivalent to an 84% drop from baseline. That means the vast majority of cancer cells were incapacitated by a drug generated right where it was needed, minimizing damage to healthy tissue. As Dr. Mihali explains, “The drug can have a concentrated local effect if we use our nanorobot to specifically target it to the cancer cells.”
Beyond medicine, the system’s reusability opens doors in industrial catalysis and environmental cleanup. Because the propulsion module is magnetic, researchers can retrieve the nanorobots after use, disassemble them, refill the payload, and send them back into action. This circular functionality—rare in nanotech—could drastically reduce costs and waste in chemical manufacturing.
While human trials are still years away, the platform’s adaptability makes it a powerful prototype. Simply swapping the payload capsule could tailor the nanorobot for diabetes treatment, toxin degradation, or even carbon capture. At just 80 nanometers in size, these machines are small enough to navigate cellular landscapes, yet smart enough to perform complex tasks on demand. In a world where precision medicine and sustainable technology are urgent goals, the Basel team has built more than a robot—they’ve built a new kind of tool, one molecule at a time.